glp-1 in development What is the pipeline for future medications for obesity? Oral Small-Molecule GLP-1 Receptor Agonists:

Rolling creates a gentle swirling motion that encourages dissolution without the mechanical force that can break peptide bonds

Over time, the body develops some tolerance to the gastric slowing effect, so their gastric emptying delay is less acute (and thus they have milder postprandial effect relative to short-acting ones) ( [112] ) ( [113] )

doi: 10.1056/NEJMoa2032183 20 FoxCKAuerbachPBarrientos-PrezMGiesIHalePMMarcusCet al

GLP-1 medications, such as Ozempic, Wegovy, Mounjaro, and Zepbound are now prescribed commonly for people diagnosed with Type 2 diabetes and/or obesity

Although some studies have raised concerns about pancreatitis and thyroid-related risks, the current evidence does not conclusively establish causality

There were no ICP lowering agents or addition of headache preventative drugs started during the study